Burden of methicillin-resistant Staphylococcus aureus pneumonia among hospitalized patients in Lebanon and Saudi Arabia
Infection and Drug Resistance
Althaqafi AO1, Matar MJ2, Moghnieh R3, Alothman AF4, Alenazi TH5, Farahat F1, Corman S6, Solem CT6, Raghubir N7, Macahilig C8, Haider S9, Stephens JM6.
1Department of Infection Prevention and Control, King Abdullah International Medical Research Center, King Saud bin AbdulAziz University for Health Sciences, Jeddah, Kingdom of Saudi Arabia.
2Department of Infectious Disease, Notre Dame de Secours University Hospital, Byblos.
3Makassed General Hospital, Beirut, Lebanese Republic.
4Department of Medicine, King Abdulaziz Medical City, Central Region, Ministry of National Guard Health Affairs.
5Infection Prevention & Control Department, King Abdulaziz Medical City-Riyadh (KAMC), Kingdom of Saudi Arabia.
6Real World Evidence: Data Analytics Center of Excellence, Pharmerit International, Bethesda, MD.
7Medical Affairs, Pfizer, New York, NY.
8Medical Data Analytics, Parsippany, NJ.
9Outcomes & Evidence, Global Health and Value, Pfizer, Groton, CT, USA.
Year of Publication:
The objective of this study is to describe the real-world treatment patterns and burden of suspected or confirmed methicillin-resistant Staphylococcus aureus (MRSA) pneumonia in Saudi Arabia and Lebanon.
A retrospective chart review study evaluated 2011-2012 data from hospitals in Saudi Arabia and Lebanon. Patients were included if they had been discharged with a diagnosis of MRSA pneumonia, which was culture proven or suspected based on clinical criteria. Hospital data were abstracted for a random sample of patients to capture demographics (eg, age and comorbidities), treatment patterns (eg, timing and use of antimicrobials), hospital resource utilization (eg, length of stay), and clinical outcomes (eg, clinical status at discharge and mortality). Descriptive results were reported using frequencies or proportions for categorical variables and mean and standard deviation for continuous variables.